P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)
Ruben Niesvizky,Paul G. Richardson,Andrew Yee,Ajay K. Nooka,Marc S. Raab,Kenneth H. Shain,Nashat Y. Gabrail,Jeffrey Matous,Amit Agarwal,James E. Hoffman,Sumit Madan,John M. Pagel,Jesus San Miguel,Philippe Moreau,Maria-Victoria Mateos,Thierry Facon,David Tamang,Simon S. Jones,Robert J Markelewicz,Catherine Wheeler,Nikolaus S. Trede,Noopur Raje,Evangelos Terpos,William I. Bensinger +23 more
TL;DR: New data is presented on safety and efficacy of the ACY-241/Pom/Dex combination in patients with relapsed or relapsed-and-refractory multiple myeloma and the recommended dose for further development.
Journal ArticleDOI
The KDM3A-KLF2-IRF4 Axis Maintains Myeloma Cell Survival
Hiroto Ohguchi,Teru Hideshima,Manoj Bhasin,Gullu Gorgun,Loredana Santo,Michele Cea,Naoya Mimura,Rikio Suzuki,Yu-Tzu Tai,Ruben D. Carrasco,Noopur Raje,Paul G. Richardson,Hideo Harigae,Takaomi Sanda,Kenneth C. Anderson +14 more
TL;DR: It is confirmed that expression of KLF2 and IRF4 was downregulated after knockdown of KDM3A by quantitative realtime PCR and immunoblots in RPMI82226, MM.
Journal ArticleDOI
The association between hepatocellular carcinoma and direct‐acting anti‐viral treatment in patients with decompensated cirrhosis
Ali Jibran Mecci,Polychronis Kemos,Clifford Leen,Adam Lawson,Paul G. Richardson,Salim I. Khakoo,Kosh Agarwal,David Mutimer,William Rosenberg,Graham R. Foster,William L. Irving +10 more
TL;DR: Direct‐acting anti‐viral therapy (DAA) has transformed hepatitis C virus care, particularly in patients with decompensated cirrhosis, but their impact on hepatocellular carcinoma (HCC) remains unclear.
Journal ArticleDOI
S824 a phase 3 randomized, open-label, multicenter study of isatuximab, pomalidomide, and low-dose dexamethasone vs pomalidomide and low-dose dexamethasone in relapsed/refractory multiple myeloma (rrmm)
M. Attal,Paul G. Richardson,S.V. Rajkumar,J. San-Miguel,M. Beksac,Ivan Spicka,Xavier Leleu,Fredrik Schjesvold,P. Moreau,M.A. Dimopoulos,J.S.-Y. Huang,Jiri Minarik,Michele Cavo,H.M. Prince,S. Mace,K.P. Corzo,F. Campana,S. Le-Guennec,F. Dubin,K.C. Anderson +19 more
Journal ArticleDOI
Emerging drugs in multiple myeloma.
Irene M. Ghobrial,Xavier Leleu,Evdoxia Hatjiharissi,Teru Hideshima,Constantine S. Mitsiades,Robert L. Schlossman,Kenneth C. Anderson,Paul G. Richardson +7 more
TL;DR: The role of novel therapeutic agents in multiple myeloma, and the promising effect of multiple new agents in development are summarized.